From: Polypharmacy in patients with multiple sclerosis: a gender-specific analysis
Drugs | Female (N = 218) | Male (N = 88) | p valueFi | FDRFi |
---|---|---|---|---|
Frequency of medication groupsc | Frequency of medication groupsc | |||
DMDs | 92.7% | 90.9% | 0.641 | 0.859 |
Gastrointestinal drugs | 42.7% | 45.5% | 0.703 | 0.859 |
Thrombosis prophylactics | 37.6% | 45.5% | 0.246 | 0.673 |
Osteoporosis drugs | 34.4% | 37.5% | 0.692 | 0.859 |
Dietary supplements | 33.9% | 23.9% | 0.101 | 0.556 |
Sedatives | 30.7% | 23.9% | 0.265 | 0.673 |
Analgesics | 28.0% | 20.5% | 0.196 | 0.673 |
Antihypertensives | 23.9% | 28.4% | 0.467 | 0.835 |
Thyroid drugs | 20.2% | 1.1% | < 0.001 | < 0.001 |
Antidepressants | 19.7% | 15.9% | 0.518 | 0.835 |
Aconuresis drugs | 18.8% | 18.2% | 1.000 | 1.000 |
Antispasmodics | 17.9% | 31.8% | 0.010 | 0.110 |
Anticonvulsants | 16.5% | 18.2% | 0.738 | 0.869 |
Contraceptives | 16.1% | 0.0% | < 0.001 | < 0.001 |
Common cold remedies | 11.9% | 8.0% | 0.416 | 0.808 |
Antiinfectives | 8.7% | 4.5% | 0.242 | 0.673 |
Cholesterol-lowering drugs | 6.9% | 11.4% | 0.248 | 0.673 |
Fampridine | 6.0% | 14.8% | 0.021 | 0.173 |
Diabetes drugs | 5.5% | 3.4% | 0.567 | 0.835 |
Antiallergics | 5.0% | 2.3% | 0.361 | 0.794 |
Anti-Parkinson drugs | 5.0% | 3.4% | 0.764 | 0.869 |
Menopause medications | 5.0% | 0.0% | 0.038 | 0.251 |
Eye drops | 4.6% | 1.1% | 0.187 | 0.673 |
Asthma drugs | 2.3% | 1.1% | 0.677 | 0.859 |
Dermatics | 2.3% | 0.0% | 0.326 | 0.768 |
Antidementives | 1.8% | 0.0% | 0.582 | 0.835 |
IT for comorbidities | 1.8% | 3.4% | 0.414 | 0.808 |
Migraine medications | 1.4% | 0.0% | 0.560 | 0.835 |
Neuroleptics | 1.4% | 0.0% | 0.560 | 0.835 |
Antivertiginous drugs | 0.9% | 0.0% | 1.000 | 1.000 |
Fatigue drugs | 0.5% | 2.3% | 0.200 | 0.673 |
Uricostatics | 0.5% | 0.0% | 1.000 | 1.000 |
VRA | 0.5% | 0.0% | 1.000 | 1.000 |